PEGylated Versus Non-PEGylated ÃÂ³ [email protected] Nanoparticles
Benyettou F, Hardouin J, Lecovey M, Jouni H and Motte L*
Laboratoire CSPBAT UMR CNRS 7244, Université Paris 13, 74 Rue Marcel Cachin, 93017 Bobigny France
- *Corresponding Author:
- Motte L
Laboratoire CSPBAT UMR CNRS 7244
Université Paris 13, 74 Rue Marcel Cachin
93017 Bobigny France
E-mail: [email protected]
Received Date: April 04, 2012; Accepted Date: May 08, 2012; Published Date: May 12, 2012
Citation:Benyettou F, Hardouin J, Lecovey M, Jouni H, Motte L (2012) PEGylated Versus Non-PEGylated γFe2O3@Alendronate Nanoparticles. J Bioanal Biomed 4:039-045. doi:10.4172/1948-593X.1000062
Copyright: © 2012 Benyettou F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Thanks to their magnetic properties, superparamagnetic iron oxide nanoparticles are considered as a good delivery vehicle after grafting a therapeutical drug on their surface. For additional “stealth” characteristics, PEGylation of surfaces is necessary. The presence of PEG chains divert nanoparticles from their preferred target, the liver macrophages and increased the particle time circulation. In this work, PEG chain is added to an anticancer drug Alendronate. This molecule is grafted on iron oxide nanoparticle surface in one step surface functionalization method. The in vitro cytotoxic efficiency of γ-Fe2O3- Alendronate-PEG nanocrystals is compared with that of free Alendronate, Alendronate-PEG and γ-Fe2O3- Alendronate nanocrystals.